Increased Serum Levels of LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease: Possible Role in Hepatic Inflammation

Abstract

Objectives:The tumor necrosis factor superfamily member 14, LIGHT (homologous to lymphotoxin, exhibits inducible expression, and competes with HSV glycoprotein D for herpes virus entry mediator (HVEM), a receptor expressed by T lymphocytes), has been involved in various autoimmune disorders and has been shown to influence hepatic lipid metabolism. We hypothesized that LIGHT could also have a pathogenic role in nonalcoholic fatty liver disease (NAFLD).Methods:Serum levels of LIGHT in NAFLD patients and control subjects, as well as LIGHT and interleukin (IL)-8 released from Huh7 (human hepatoma cell line) hepatocytes, were determined by enzyme-linked immunosorbent assay. The mRNA expression of LIGHT in the liver tissue and mRNA levels of LIGHT and IL-8 in Huh7 hepatocytes were assessed by real-time quantitative reverse transcription-PCR.Results:(i) Serum levels of LIGHT were significantly elevated in NAFLD patients (n=66) as compared with healthy controls (n=16), with no differences between simple steatosis (n=34) and nonalcoholic steatohepatitis (NASH) (n=32). (ii) Within the liver, NAFLD patients (n=14) had significantly increased mRNA levels of the two LIGHT receptors, herpes virus entry mediator and lymphotoxin β receptor (LTβR), as compared with controls (n=7), with no difference between simple steatosis (n=8) and NASH (n=6). (iii) LIGHT markedly increased the release of IL-8 in Huh7 hepatocytes in a time- and dose-dependent manner. (iv) The reactive oxygen species (ROS) H ₂ O₂ (hydrogen peroxide) enhanced the LIGHT-mediated release of IL-8 in Huh7 hepatocytes.Conclusion:We show increased levels of LIGHT and its two membrane-bound receptors in NAFLD, potentially promoting hepatic inflammation through ROS interaction. Our findings should encourage further studies on the role of LIGHT in NAFLD development and progression.

Citation: Clinical and Translational Gastroenterology (2015) 6, e95; doi:http://dx.doi.org/10.1038/ctg.2015.23

Web End =10.1038/ctg.2015.23

& 2015 the American College of Gastroenterology All rights reserved 2155-384X/15 http://www.nature.com/ctg

Web End =www.nature.com/ctg

Kari Otterdal, MSc, PhD1,2, John W.illy Haukeland, MD, PhD3, Arne Yndestad, MPharm, PhD1,2,4, Tuva B. Dahl, MSc, PhD1,2, Sverre Holm, MSc, PhD1, Filip M. Segers, MSc, PhD1, Ivar P. Gladhaug, MD, PhD2,5, Zbigniew Konopski, MD, PhD3,Jan K.ristian Dams, MD, PhD6,7, Bente Halvorsen, MSc, PhD1,2,4 and Pl Aukrust, MD, PhD1,2,4,8

OBJECTIVES: The tumor necrosis factor superfamily member 14, LIGHT (homologous to lymphotoxin, exhibits inducible expression, and competes with HSV glycoprotein D for herpes virus entry mediator (HVEM), a receptor expressed by T lymphocytes), has been involved in various autoimmune disorders and has been shown to influence hepatic lipid metabolism. We hypothesized that LIGHT could also have a pathogenic role in nonalcoholic fatty liver disease (NAFLD).

METHODS: Serum levels of LIGHT in NAFLD patients and control subjects, as well as LIGHT and interleukin (IL)-8 released from Huh7 (human hepatoma cell line) hepatocytes, were determined by enzyme-linked immunosorbent assay. The mRNA expression of LIGHT in the liver tissue and mRNA levels of LIGHT and IL-8 in Huh7 hepatocytes were assessed by real-time quantitative reverse transcription-PCR.

RESULTS: (i) Serum levels of LIGHT were significantly elevated in NAFLD patients (n = 66) as compared with healthy controls (n = 16), with no differences between simple steatosis (n = 34) and nonalcoholic steatohepatitis (NASH) (n = 32). (ii) Within the liver, NAFLD patients (n = 14) had significantly increased mRNA levels of the two LIGHTreceptors, herpes virus entry mediator and lymphotoxin receptor (LTR), as compared with controls (n = 7), with no difference between simple steatosis (n = 8) and NASH (n = 6). (iii) LIGHT markedly increased the release of IL-8 in Huh7 hepatocytes in a time- and dose-dependent manner. (iv) The reactive oxygen species (ROS) H2O2 (hydrogen peroxide) enhanced the LIGHT-mediated release of IL-8 in Huh7 hepatocytes.

CONCLUSION: We show increased levels of LIGHT and its two membrane-bound receptors in NAFLD, potentially promoting hepatic inflammation through ROS interaction. Our findings should encourage further studies on the role of LIGHT in NAFLD development and progression.

Clinical and Translational Gastroenterology (2015) 6, e95; doi:http://dx.doi.org/10.1038/ctg.2015.23

Web End =10.1038/ctg.2015.23 ; published online 2 July 2015Subject Category: Liver

INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with an estimated prevalence of about 20%.1 NAFLD ranges from simple fat deposition to nonalcoholic steatohepatitis (NASH), characterized by steatosis, inflammation, and progressive fibrosis, ultimately leading to cirrhosis and end-stage liver disease.1,2 NAFLD is frequently associated with obesity, dyslipidemia, and insulin resistance, disorders that constitute metabolic syndrome.3 Although enhanced oxidative stress, inflammation, and metabolic disturbances, potentially representing interacting mechanisms, have been implicated in the pathogenesis of NAFLD, the mechanisms that underlie the initiation and progression of this disorder are still not clear.46

LIGHT (homologous to lymphotoxin, exhibits inducible expression, and competes with HSV glycoprotein D for herpes virus entry mediator (HVEM), a receptor expressed by

Increased Serum Levels of LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease: Possible Role in Hepatic Inflammation

T lymphocytes) is a 29 kDa type 2 transmembrane protein belonging to the tumor necrosis factor (TNF) superfamiliy (TNFSF).7 LIGHT/TNFSF14 is primarily expressed on T cells and dendritic cells, but has also been found on platelets, monocytes, and granulocytes, being involved in innate and adaptive immune responses, as well as in the regulation of cell survival and proliferation.7,8 LIGHT binds to the HVEM (HVEM/TNFRSF14), and is also a shared ligand with membrane-bound lymphotoxin for LTR/TNFRSF3.7 Studies in animal models and some clinical studies indicate that LIGHT may be crucial for the development of various autoimmune and inflammatory disorders,9,10 and has also

been implicated in the pathogenesis of atherosclerosis.11,12 In

addition, LIGHT has been found to promote hepatic inflammation in two independent experimental hepatitis models(i.e., hepatitis induced by concanavalin A and Listeria monocytogenes),13 and has been reported to modulate lipid

1Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; 2Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; 3Department of Gastroenterology, Oslo University Hospital Ullevl, Oslo, Norway; 4K.G. Jebsen Inflammatory Research Center, Oslo, Norway; 5Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital Rikshospitalet, Oslo, Norway; 6Centre of Molecular Inflammation Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, St Olavs Hospital, Trondheim, Norway; 7Department of Infectious Diseases, St Olavs Hospital, Trondheim, Norway and 8Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, NorwayCorrespondence: Kari Otterdal, MSc, PhD, Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Sognsvannsveien 20, Oslo 0027, Norway. E-mail: mailto:[email protected]

Web End [email protected] Received 30 October 2014; accepted 18 March 2015

LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease Otterdal et al.

2

homeostasis through interaction with LTR, at least partly through inhibition of hepatic lipase expression in hepatocytes.14

Based on its role in inflammatory disorders such as atherosclerosis, we hypothesized a possible role for LIGHT in NAFLD, as similar pathogenic interactions between inflammation and lipid metabolism are involved. In the present study, this hypothesis was tested through various experimental approaches including in vivo studies in NAFLD patients as well as in vitro studies in hepatocytes.

METHODS

Patients and controls. The study population is part of a published cohort,15 and all patients with available serum samples for cytokine analyses were included in this study (66 patients with biopsy-verified NAFLD; 34 with simple steatosis and 32 with NASH) (Table 1). In NASH, the grade of inflammation was mild (n = 24) or moderate to severe (n = 8). Fibrosis was observed in 30 patients (stage 1, n = 21; stage 2, n = 5; stage 3, n = 3; and stage 4, n = 1), including 5 patients without necroinflammation. Type 2 diabetes mellitus and the metabolic syndrome (by the Adult Treatment Panel III definition)16 were present in 26% and 71% of the cases, respectively. No other liver diseases (e.g., chronic hepatitis B or C virus infection, hemochromatosis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, or malignancy) were present. None of the patients had ingested any known hepatotoxic medications or herbal products, and the average alcohol consumption was o24 g per day in all subjects. For comparison, serum samples were also obtained from 16 age-, sex-, and ethnicity-matched healthy controls, all with serum levels of alanine aminotransferase (ALT) within the normal range (Table 1). None of the controls took any medication regularly, the alcohol consumption was o24 g per day and the body mass index (BMI) was o27 kg/m2 in all individuals.

In the study of hepatic expression of LIGHT/HVEM/LTR, we included another 14 patients (age: 48.1 (9.7) years; BMI:29.8 (2.1) kg/m2; ALT 82 (37273) U/l) with biopsy-verified simple steatosis (n = 8) or NASH (n = 6). Seven patients who underwent hepatic resection for liver metastasis from colorectal cancer (n = 6) or carcinoid (n = 1) served as controls (age: 62.7 (7.5) years; BMI: 26.6 (3.3) kg/m2; ALT: 22 (1436) U/l). In the controls, the liver specimens were carefully evaluated for cancer cell infiltration both macroscopically and microscopically. However, although the control specimens showed few infiltrating lymphocytes, we cannot totally exclude that these specimens contain tumor-infiltrating T cells with low expression of LIGHT.17 Written informed

consent for participation in the studies was obtained from all individuals. The regional Ethical Committee approved the studies, which were conducted according to the Declaration of Helsinki. Serum samples for the study were collected and stored as described previously.15

Liver biopsy and histological examinations. All biopsies were obtained using a biopsy gun and were snap frozen in liquid nitrogen and thereafter stored at 80 C (for the study of hepatic gene expression) or fixed in formalin. Slides were routinely stained with hematoxylin/eosin, Masson trichrome or AFOG, Gomori and Perls staining for iron, and examined by two liver pathologists blinded for clinical data. Histological examinations showed normal liver tissue for the all controls. Steatosis was defined when fat droplets were present in 45% of hepatocytes. NASH was defined when either ballooning and lobular inflammation or typical lobular fibrosis was present in addition to steatosis. Fibrosis was staged as follows: 0 = no fibrosis, 1 = pericellular fibrosis or isolated portal fibrosis, 2 = combined pericellular and portal fibrosis, 3 = bridging fibrosis, and 4 = cirrhosis.

Hepatocyte cultures. Huh7 (human hepatoma cell line), obtained from the Health Science Research Resources Bank (JCRB0403; Osaka, Japan), were cultured in Dulbeccos modified Eagle's medium (Sigma-Aldrich, St Louis, MO), supplemented with 10% heat-inactivated fetal calf serum, to 7085% confluence, and then stimulated with different concentrations (1100 ng/ml) of recombinant LIGHT (R&D Systems, Minneapolis, MN). In a separate set of experiments, the cells were incubated with LIGHT with and without different concentration of H2O2 (hydrogen peroxide; Sigma-Aldrich).

In these coculture experiments, we used 300 ng/ml LIGHT to ensure a proper and significant response of LIGHT. After incubation, cell-free supernatants and cell pellets were harvested and stored at 80 C.

Real-time quantitative RT-PCR. Total RNA was isolated from frozen liver specimens using Trizol reagent (Life Technologies, Invitrogen, San Diego, CA) and Huh7 cells using RNeasy mini columns (Qiagen, Hilden, Germany), DNase treated, and stored at 80 C. cDNA was synthesized using a high-capacity cDNA archive kit (Applied Biosystems, Foster City, CA). Primers for LIGHT, HVEM, and LTR were designed using the Primer Express software, version 2 (Applied Biosystems). Primer sequences could be provided upon request. Quantification of mRNA was performed using the ABI Prism 7000 (Applied Biosystems). Gene expression

Table 1 Anthropometric data and serum ALT for healthy controls, patients with simple steatosis, and patients with NASH

Controls (n = 16) Simple steatosis (n = 34) NASH (n = 32) P value

Age (years), mean (s.d.) 42.1 (10.2) 44.3 (12.6) 44.9 (12.6) 0.748 Sex, male/female 8/8 19/15 18/14 0.908 Body mass index (kg/m2), mean (s.d.) 23.0 (2.4) 29.5 (3.7) 31.6 (4.7) o0.001

S-ALT (U/l), median (interquartile range) 22 (14) 73 (62) 98 (56) o0.001

ALT, alanine aminotransferase; NASH, nonalcoholic steatohepatitis; S-ALT, serum ALT.

P values represent comparisons between all three groups.

Clinical and Translational Gastroenterology

LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease Otterdal et al.

3

of the housekeeping genes GAPDH and -actin were used for normalization. SYBR Green assays were performed with the qPCR Master Mix for Power SYBR Green I (Eurogentech, Seraing, Belgium).

Measurement of cytokines by enzyme immunoassay. Concentrations of LIGHT, interleukin-8 (IL-8), IL-6, monocyte chemoattractant protein-1/CCL2, and TNF were measured by enzyme immunoassays obtained from R&D Systems. The intraand intercoefficient of variation were o10% for all assays.

Statistical analyses. This study was designed to analyze the difference in serum or plasma levels of cytokines or more specific LIGHT between NAFLD patients and healthy controls. We were looking for rather large differences (450%

changes from reference group), and found that 50 NAFLD patients and 15 healthy controls would have 490% power to detect a difference between means of 1.5 with an of 0.05 (two-tailed). Data were analyzed using SPSS 14.0 (SPSS, Chicago, IL) and GraphPad Prism 5 (La Jolla, CA, USA). T-test or MannWhitney U-test were used for univariate comparisons between groups as appropriate. Correlations were calculated by the Spearman rank test. Multiple linear regression analyses were performed to explore the effects of NAFLD and NASH on serum levels of LIGHTafter adjustment for age, sex, and BMI. Probability values (two-sided) were considered significant at Po0.05.

RESULTS

Serum levels of LIGHT in NAFLD patients and healthy controls. Patients with NAFLD (n = 66) had significantly raised serum levels of LIGHT as compared with healthy controls (n = 16) (mean (s.d.): 79.1 (53.49) vs. 26.4 (24.6) pg/ ml, Po0.001), with no significant difference between simple steatosis (n = 34) and NASH (n = 32) (mean (s.d.): 85.3 (55.6)

vs. 70.4 (50.8) pg/ml, P = 0.26), simple steatosis, and NASH, respectively) (Figure 1). After adjustment for sex, BMI, and age, the diagnosis of NAFLD was still a significant predictor of LIGHT (Po0.001; Table 2). Moreover, within the NAFLD goup, there was no difference in LIGHT levels between those who met (n = 47) and those who did not meet (n = 19) the criteria for metabolic syndrome (mean (s.d.): 79.1 (55.1) vs.75.5 (50.5) pg/ml, P = 0.80). Also, there was no difference in serum levels of LIGHT when comparing those with and without fibrosis (data not shown).

There are a few studies on increased LIGHT levels in obesity associated with elevated levels of triglycerides and impaired glycemic control.18,19 In the present study, however, we found no

correlation between LIGHT levels and BMI in either patients (r = 0.13, P = 0.30) or controls (r = 0.16, P = 0.56). Moreover, within the NAFLD group, there was no difference in LIGHT levels between those with BMI above (n = 34) and below 30 kg/m2 (n = 32) (mean (s.d.): 72.2 (49.4) vs. 84.4 (57.8) pg/ml, P = 0.36, above and below 30 kg/m2, respectively).

Hepatic gene expression of LIGHT and its receptors in NAFLD patients and controls. To further characterize the regulation of LIGHT in NAFLD, we examined the mRNA levels of LIGHT and its corresponding receptors, HVEM and LTR, in liver biopsies from 14 patients with NAFLD (eight with simple steatosis and six with NASH) and seven controls. As shown in Figure 2, mRNA levels of HVEM and LTR were both significantly enhanced in NAFLD with no differences between simple steatosis and NASH. In contrast, LIGHT gene expression did not differ between patients and controls (Figure 2).

LIGHT enhances IL-8 release in Huh7 hepatocytes. Hepatic inflammation is an important feature of NAFLD-related disease. To elucidate any potential pathogenic role of LIGHT in NAFLD, we next examined the ability of LIGHT to promote the production and release of prototypical inflammatory cytokines in Huh7 hepatocytes. Whereas LIGHT had no effect on the release of IL-6, TNF, and monocyte chemoattractant protein-1,

Figure 1 Levels of LIGHT (homologous to lymphotoxin, exhibits inducible expression, and competes with HSV glycoprotein D for herpes virus entry mediator, a receptor expressed by T lymphocytes) in patients and controls. Serum levels of LIGHTwere assessed by enzyme immunoassay, in healthy control subjects (n = 16), patients with simple steatosis (n = 34), and patients with nonalcoholic steatohepatitis (NASH) (n = 32). Horizontal lines indicate median values.

Table 2 NAFLD is an independent predictor of elevated serum levels of LIGHT after adjustment for sex, BMI, and age (adj. R2 = 0.135)

Dependent variable Explanatory variable 95% CI for P value

LIGHT NAFLD present 64.9 30.2, 100.0 o0.001 Sex (ref. = male) 14.5 8.7, 37.7 0.218 BMI (per kg/m2) 1.5 4.3, 1.2 0.277 Age (per year) 0.4 1.4, 0.6 0.408

BMI, body mass index; CI, confidence interval; LIGHT, homologous to lymphotoxin, exhibits inducible expression, and competes with HSV glycoprotein D for herpes virus entry mediator, a receptor expressed by T lymphocytes; NAFLD, nonalcoholic fatty liver disease.

Serum LIGHT levels are estimated to be 64.9 pg/ml higher in NAFLD patients as compared with controls according to the model, which explains 13.5% of the variability of serum LIGHT levels (adj. R2 = 0.135). Values show the degree of association for each parameter with NAFLD.

Clinical and Translational Gastroenterology

LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease Otterdal et al.

4

Figure 2 Levels of LIGHT (homologous to lymphotoxin, exhibits inducible expression, and competes with HSV glycoprotein D for herpes virus entry mediator (HVEM), a receptor expressed by T lymphocytes), HVEM, and lymphotoxin

receptor (LTR) in liver biopsies from patients and controls. mRNA levels of (a) LIGHT and its corresponding receptors, (b) HVEM and (c) LTR, in liver biopsies from control subjects (n = 7), patients with simple steatosis (n = 8), and patients with nonalcoholic steatohepatitis (NASH) (n = 6). mRNA levels were quantified by real-time reverse transcription-PCR (RT-PCR), in relation to the control gene GAPDH (glyceraldehyde 3-phosphate dehydrogenase). Data are given as mean s.e.m. *Po0.05 vs. control subjects.

it markedly enhanced the IL-8 response in a time- and dose-dependent manner (Figure 3) both on protein and mRNA level.

H2O2 augments the LIGHT-mediated release of IL-8 in Huh7 hepatocytes. Increased oxidative stress has been implicated in the pathogenesis of NAFLD.4 As shown in Figure 4, H2O2 increased the release of IL-8 from Huh7 cells, and notably, it also enhanced the stimulating effect of LIGHT on IL-8 release in these cells. Similar effects or even stronger

effects were seen at the mRNA levels (Figure 4). LIGHT interact with HVEM and LTR, and while HVEM in general showed very low expression in these cells, LTR was clearly present and H2O2 enhanced the expression of

LTR, in particular when combined with LIGHT stimulation (Figure 5).

DISCUSSION

In the present study, we show that NAFLD patients are characterized by increased serum levels of the TNFSF member LIGHT as well as enhanced hepatic expression of its receptors, HVEM and LTR, with no significant differences between simple steatosis and NASH. Our in vitro findings in Huh7 hepatocytes suggest that LIGHT induces an increased release of the inflammatory chemokine IL-8 in these cells, with enhancing effects when coincubated with H2O2. Our findings suggest that LIGHT-mediated inflammation could be involved in NAFLD pathogenesis, potentially involving interaction with enhanced oxidative stress. It could be argued that in contrast to serum levels, LIGHT levels were not increased in the liver from NAFLD patients. However, the hepatic expression of the LIGHT receptors were significantly upregulated in NAFLD, indicating a possibility for LIGHT-mediated pathology in NAFLD even if LIGHT itself is not upregulated within the liver.

Several inflammatory cytokines have been implicated in the pathogenesis of NAFLD including TNF-related molecules such as TNFTNFSF2,20 Fas ligand (TNFSF6),21 TNF-related apoptosis inducing ligand (TNFSF10),22 and osteoprotegerin (TNFRSF11b).23 Experimental studies have previously shown that LIGHT could promote hepatic inflammation and metabolic disturbances within the liver.13,14 This cytokine has also

been linked to the pathogenesis of various inflammatory and autoimmune disorders such as inflammatory bowel disease, nephritis, and rheumatoid arthritis.10,2426 However, to the

best of our knowledge, this is the first report of increased serum levels of LIGHT, as well as increased hepatic expression of its receptors, HVEM and LTR, in patients with NAFLD. Celik et al.27 have reported elevated LIGHT levels in patients with hepatitis C virus infection and in patients with rheumatoid arthritis, and we have previously shown elevated LIGHT levels in patients with coronary artery disease.28

However, although raised LIGHT levels are not specific for NAFLD, LIGHT could still have a pathogenic role in this disorder. In fact, a common feature of several inflammatory cytokines is that they are elevated and have a pathogenic role in a magnitude of disorders with inflammation as a common feature.

Unfortunately, we have no data on the cellular source of LIGHT in fatty liver. In general, LIGHT is strongly expressed by activated T cells, and is also found in granulocytes, immature dendritic cells, and platelets.7,8 In the liver, LIGHT+ T cells have been shown to inhibit hepatic lipase,14 and hepatic NK1.1+ T cells have been shown to produce LIGHT during experimental hepatitis.13 However, as soluble LIGHT may be rapidly cleaved from its membrane-bound form, mediating LIGHT-driven inflammation, the cellular source of LIGHT can be difficult to prove. Nonetheless, it is not inconceivable that the cellular source of LIGHT in NAFLD may be infiltrating T cells.

Clinical and Translational Gastroenterology

LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease Otterdal et al.

5

Figure 3 Impact of LIGHT (homologous to lymphotoxin, exhibits inducible expression, and competes with HSV glycoprotein D for herpes virus entry mediator (HVEM), a receptor expressed by T lymphocytes) on the expression of interleukin-8 (IL-8) in Huh7 (human hepatoma cell line) hepatocytes. Effect of recombinant human LIGHT (ng/ml) on the expression of IL-8 in Huh7 hepatocytes after (a and b) 2 h and (c and d) 8 h stimulation. Left panels show mRNA levels of IL-8 from cell lysates, as assessed by real-time reverse transcription-PCR (RT-PCR), in relation to the control gene -actin, and right panels show protein levels of IL-8 measured in the supernatant from cells by enzyme immunoassay. Data are given as mean s.e.m., n = 6. *P = 0.06, *Po0.05, **Po0.01, and ****Po0.0001 vs. US (unstimulated).

Whereas several LIGHT effects seems to be mediated by its membrane-bound form, in particular on T cells (e.g., metabolic effects within the liver),7,10,14 soluble LIGHT has been found

to promote hepatic inflammation.13 In the present study, we show that soluble LIGHT is a potent inducer of IL-8 production and release in Huh7 hepatocytes. Moreover, in line with studies in experimental hepatitis,13 the LIGHT-mediated inflammatory response in Huh7 hepatocytes seemed to be mediated through LTR, as HVEM was expressed at very low levels in these cells. Thus, while HVEM is prominently expressed in T cells, LTR is expressed in stromal cells or non-lymphoid hematopoietic cells including hepatocytes.7,13 Yet, although HVEM was scarcely expressed in Huh7 hepatocytes, we cannot exclude an inflammatory interaction between LIGHT and HVEM during hepatic inflammation through T- cell-related mechanisms. However, even in experimental hepatitis, abundant with T cells and

NK-T cells, the LIGHT-mediated hepatic inflammation seems primarily to be mediated through LTR.13

Enhanced oxidative stress has been implicated to have an important role in the development and progression of NAFLD.4 In the present study, we show that the reactive oxygen species H2O2, in addition to promote IL-8 release in itself, enhanced the LIGHT-induced production and release of IL-8. IL-8 is a potent inflammatory cytokine that could promote generation of reactive oxygen species in leukocytes,29 and has also been linked to development of NAFLD.30 If IL-8 is operating in vivo within the liver, the interaction between LIGHT, H2O2, and IL-8

could potentially be part of a pathogenic loop during NAFLD progression. Moreover, although there was no difference between the expression of LIGHT and LTR between simple steatosis and NASH, H2O2 level is presumable higher in

NASH, potentially resulting in increased LIGHT-mediated

Clinical and Translational Gastroenterology

LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease Otterdal et al.

6

Figure 4 Impact of LIGHT (homologous to lymphotoxin, exhibits inducible expression, and competes with HSV glycoprotein D for herpes virus entry mediator (HVEM), a receptor expressed by T lymphocytes) on the expression of interleukin-8 (IL-8) in Huh7 (human hepatoma cell line) hepatocytes in the presence of H2O2. Huh7 hepatocytes were stimulated with recombinant human LIGHT (300 ng/ml) with or without coincubation with two different concentrations of H2O2. The panels show mRNA levels in cell lysates (a), as assessed by real-time reverse transcription-PCR (RT-PCR), in relation to the control gene -actin, and (b) protein levels in cell supernatants, as assessed by enzyme immunoassay, of IL-8 after 5 and 18 h stimulation, respectively. Data are given as mean s.e.m., n = 8. *Po0.05, **Po0.01, and ****Po0.0001 vs. US (unstimulated).

Po0.05, Po0.01, and Po0.001 vs. LIGHT when given alone.

Figure 5 Effect of LIGHT (homologous to lymphotoxin, exhibits inducible expression, and competes with HSV glycoprotein D for herpes virus entry mediator (HVEM), a receptor expressed by T lymphocytes) on the regulation of lymphotoxin

receptor (LTR) in Huh7 (human hepatoma cell line) hepatocytes in the presence of H2O2. mRNA levels of LTR, as assessed by real-time reverse transcription-PCR (RT-PCR) in relation to the control gene -actin, were analyzed in cell lysates after 5 h stimulation with 300 ng/ml recombinant human LIGHT. Data are given as mean s.e.m., n = 8. *Po0.05 vs. US (unstimulated); Po0.05 vs. LIGHT when given alone.

Figure 6 Postulated mechanism of LIGHT (homologous to lymphotoxin, exhibits inducible expression, and competes with HSV glycoprotein D for herpes virus entry mediator (HVEM), a receptor expressed by T lymphocytes) in nonalcoholic fatty liver disease (NAFLD). Within the liver, LIGHT, potentially produced by infiltrating T cells, binds to its receptors, lymphotoxin receptor (LTR) and HVEM, and is found to be upregulated in NAFLD, leading to induction and release of IL-8. IL-8 could promote

H2O2 production, which in turn will increase LIGHT-mediated IL-8 release through upregulation of its receptors, creating a pathogenic loop that may contribute to the development and progression of NAFLD.

effects. On the other hand, LIGHT has also been shown to promote liver regeneration31 and to counteract the TNF-induced apoptosis in hepatocytes,32 and the role of LIGHT in NAFLD is far from clear.

The present study has some limitations such as relatively low number of patients in particular in the analyses of LIGHT expression in the liver, and the number of patients with simple steatosis and NASH could have been too low to detect

differences between these two NAFLD subgroups. In addition, the control samples for liver specimens were not ideal and we lack data on the cellular source of LIGHT. However, we suggest that our findings indicate that LIGHT-mediated inflammation could be operating in NAFLD, involving interactions between IL-8 and oxidative stress, potentially representing a pathogenic loop in the deleveopment and progression of NAFLD (Figure 6). Our findings should encourage further studies on the role of LIGHT in NAFLD development and progression.

Clinical and Translational Gastroenterology

LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease Otterdal et al.

7

CONFLICT OF INTEREST

Guarantor of the article: Kari Otterdal, MSc, PhD.

Author contributions: K.O., contributions to the conception and design of study, performing the in vitro experiments, performing analyses and interpretation of data, drafting the manuscript; JWH/IPG/ZK, contributions to the conception and design of study, collection of patient and control material; AY/ SH/FMS, performing analyses and interpretation of data; TBD, culturing the hepatocytes, performing analyses and interpretation of data; JKD/BH, contributions to the conception and design of study, involved in interpretation of data; PA, contributions to the conception and design of study, drafting the manuscript. All the authors have read and approved the manuscript.

Financial support: The Norwegian Research Council, University of Oslo, the Southern and Eastern Norway Regional Health Authority and Inven2.

Potential competing interests: None.

Acknowledgments. We thank Ellen Lund Sagen for excellent technical assistance.

Study Highlights

WHAT IS CURRENT KNOWLEDGE Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with an estimated prevalence of about 20%.

A possible role for tumor necrosis factor superfamily

member 14 (TNFSF14)/homologous to lymphotoxin, exhibits inducible expression, and competes with HSV glycoprotein D for herpes virus entry mediator, a receptor expressed by T lymphocytes (LIGHT) in NAFLD is poorly documented.

WHAT IS NEW HERE We show increased levels of LIGHTand its two membrane-bound receptors, HVEM and LTR, in NAFLD.

LIGHT induces release of the inflammatory mediator IL-8

from hepatocytes in vitro, and the reactive oxygen species H2O2 enhance this release.

1. Bjrnsson E, Angulo P. Non-alcoholic fatty liver disease. Scand J Gastroenterol 2007; 42: 10231030.

2. Pais R, Charlotte F, Fedchuk L et al. LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 2013; 59: 550556.

3. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917923.

4. Leung TM, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol 2013; 58: 395398.

5. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lesions from genetically engineered mice. J Clin Invest 2008; 118: 829838.6. Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology 2012; 143: 11581172.

7. Schneider K, Potter KG, Ware CF. Lymphotoxin and LIGHT signaling pathways and target genes. Immunol Rev 2004; 202: 4966.

8. Otterdal K, Smith C, ie E et al. Platelet-derived LIGHT induces inflammatory responses in endothelial cells and monocytes. Blood 2006; 108: 928935.

9. Lin WW, Hsieh SL. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory disease, autoimmune disease and cancer. Biochem Pharmacol 2011; 81: 838847.

10. Ware CF. Targeting the LIGHT-HVEM pathway. Adv Exp Med Biol 2009; 647: 146155.11. Sandberg WJ, Halvorsen B, Yndestad A et al. Inflammatory interaction between LIGHTand proteinase-activated receptor-2 in endothelial cells. Potential role in atherogenesis. Circ Res 2009; 104: 6068.

12. Lee WH, Kim SH, Lee Y et al. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arterioscler Thromb Vasc Biol 2001; 21: 20042010.

13. Anand S, Yoshimura K, Choi IH et al. Essential role of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis. J Clin Invest 2006; 116: 10451051.

14. Lo JC, Wang Y, Tumanov AV et al. Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science 2007; 316: 285288.

15. Haukeland JW, Dams JK, Konopski Z et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006; 44: 11671174.

16. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 24862497.

17. Qin JZ, Upadhyay V, Prabhakar B, Maker AV. Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases. J Transl Med 2013; 11: 70.

18. Bassols J, Moreno JM, Ortega F, Ricart W, Fernandez-Real JM. Characterization of herpes virus entry mediator as a factor linked to obesity. Obesity 2010; 18: 239246.

19. Bassols J, Moreno-Navarrete JM, Ortega F, Ricart W, Fernandez-Real JM. LIGHT is associated with hypertriglyceridemia in obese subjects and increased cytokine secretion from cultured human adipocytes. Int J Obes 2010; 34: 146156.

20. Tokushige K, Takakura M, Tsuschiya-Matsushita N et al. Influence of TNF gene polymrphism in Japanese patients with NASH and simple steatosis. J Hepatol 2007; 46: 11041110.

21. Tamimi TI, Elgouhari HM, Alkhouri N et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 2011; 54: 12241229.

22. Hirsova P, Ibrahim SH, Bronk SF et al. Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis. PLoS One 2013; 22: e70599.

23. Yilmaz Y, Yonal O, Kurt R et al. Serum levels of osteoprotegrin in the spectrum of nonalcoholic fatty liver disease. Scand J Clin Lab Invest 2010; 70: 541546.

24. Krause P, Zahner SP, Kim G et al. The tumor necrosis factor family member TNFSF14 (LIGHT) is required for resolution of intestinal inflammation in mice. Gastroenterology 2014; 146: 17521762.

25. Wang J, Anders RA, Wu Q et al. Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. J Clin Invest 2004; 113: 826835.

26. Pierer M, Brentano F, Rethage J et al. The TNF superfamily member LIGHT contributes to survival and activation of synovial fibroblasts in rheumatoid arthritis. Rheumatology 2007; 46: 10631070.

27. Celik S, Shankar V, Richter A et al. Proinflammatory and prothrombotic effects on human vascular endothelial cells of immune-cell-derived LIGHT. Eur J Med Res 2009;14:147156.

28. Scholz H, Sandberg W, Dams JK et al. Enhanced plasma levels of LIGHT in unstable angina. Possible pathogenic role in foam cell formation and thrombosis. Circulation 2005;112:21212129.

29. Guichard C, Pedruzzi E, Dewas C et al. Interleukin-8 induced priminmg of neutrophil oxidative burst requeires sequential recruitment of NADPH oxidase components into lipid rafts. J Biol Chem 2005; 280: 3702137032.

30. Jarrar MH, Baranova A, Collantes R et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 412421.

31. Anders RA, Subudhi SK, Wang J et al. Contribution of the lymphotoxin beta receptor to liver regeneration. J Immunol 2005; 175: 12951300.

32. Matsui H, Hikichi Y, Tsuji I et al. LIGHT, a member of the tumor necrosis ligandsuperfamily, prevents tumor necrosis factor--mediated human primary hepatocyte apoptosis, but not

Fas-mediated apoptosis. J Biol Chem 2002; 277: 5005450061.

Clinical and Translational Gastroenterology is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the articles Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

Web End =http:// http://creativecommons.org/licenses/by-nc-nd/4.0/

Web End =creativecommons.org/licenses/by-nc-nd/4.0/

Clinical and Translational Gastroenterology